Arch Biopartners Inc. (ACHFF)
OTCMKTS · Delayed Price · Currency is USD
0.7206
+0.0180 (2.55%)
Feb 13, 2026, 10:35 AM EST
Arch Biopartners Revenue
In the fiscal year ending September 30, 2025, Arch Biopartners had annual revenue of 275.94K CAD, down -87.00%.
Revenue
275.94K CAD
Revenue Growth
-87.00%
P/S Ratio
237.38
Revenue / Employee
n/a
Employees
n/a
Market Cap
47.03M USD
Revenue Chart
* This company reports financials in CAD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Sep 30, 2025 | 275.94K | -1.85M | -87.00% |
| Sep 30, 2024 | 2.12M | 138.21K | 6.97% |
| Sep 30, 2023 | 1.98M | 1.02M | 105.63% |
| Sep 30, 2022 | 964.68K | -2.92M | -75.18% |
| Sep 30, 2021 | 3.89M | 3.82M | 5,625.22% |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Nuo Therapeutics | 2.61M |
| Harvard Apparatus Regenerative Technology | 743.00K |
| Zenith Capital | 500.00K |
| Provectus Biopharmaceuticals | 350.44K |
| ZIVO Bioscience | 209.03K |
Arch Biopartners News
- 4 days ago - Arch Biopartners Scientists Publish New Data Linking the Cytokine IL-32 to Inflammation and Diabetic Kidney Disease - GlobeNewsWire
- 4 weeks ago - Arch Biopartners Names Patrick Vink As Chairman As Claude Allary Retires - Nasdaq
- 2 months ago - Arch Biopartners Announces Ethics Approval for St. Michael's Hospital to Participate in the Phase II Cardiac Surgery-Associated AKI Trial for LSALT Peptide - GlobeNewsWire
- 3 months ago - Arch Biopartners Closes Non-Brokered Private Placement - GlobeNewsWire
- 3 months ago - Arch biopartners launches non-brokered private placement - Seeking Alpha
- 3 months ago - Arch Biopartners Arranges Non-Brokered Private Placement - GlobeNewsWire
- 5 months ago - Arch Strengthens its Position as a Leading Kidney Therapeutics Company with the Acquisition of a Breakthrough Platform to Develop New Drugs Targeting Chronic Kidney Disease (CKD) - GlobeNewsWire
- 6 months ago - Arch Biopartners Announces First Patient Successfully Dosed at Toronto General Hospital in Phase II Trial of LSALT Peptide Targeting Cardiac Surgery-Associated Acute Kidney Injury - GlobeNewsWire